logo-loader
viewMedlab Clinical Ltd

Medlab Clinical raises $5 million to help advance cannabis-based medicine NanaBis

Placement funds will help the company address short-term goals as it prepares for Phase 3 research of the NanaBis™ drug candidate program.

Medlab Clinical Ltd - Medlab Clinical raises $5 million to help advance cannabis-based medicine NanaBis
The placement was well-supported by institutional and sophisticated investors

Medlab Clinical Ltd (ASX:MDC) has raised $5 million before costs in a placement which was well supported by institutional and sophisticated investors in Australia.

The placement, which was oversubscribed, will see almost 17.86 million shares placed and the company expects that settlement will take place on Friday, December 20, 2019.

New shares are expected to be allotted on Monday, December 23, 2019.

Acova Capital and Morgans Corporate Limited acted as joint lead managers to the placement.

“Extremely pleasing” support

Medlab CEO Sean Hall said, “The support shown for the placement has been extremely pleasing and appreciated.

“These funds help the company address short-term goals as it prepares for Phase 3 research of its NanaBis™ drug candidate program.

“Medlab would like to take this opportunity to thank Morgans Corporate Limited and Acova Capital for completing the successful placement.”

The issue was within the prescribed 15% limit under ASX Listing Rule 7.1, and all shares issued pursuant to the placement will rank equally with existing ordinary shares.

Ethics Observational Study

Medlab is progressing with its Ethics Observational Study for NanaBis, a highly purified proprietary blend of cannabis molecules cannabidiol (CBD) and tetrahydrocannabinol (THC).

This pain management medicine is delivered into the body using Medlab’s patented sub-micron delivery platform NanoCelle.

The Ethics Observational Study is part of Medlab’s commitment to clinical trials pathway to drug registration for NanaBis that includes the current study close to completion at The Royal North Shore Hospital in Sydney.

This study, which is assessing real-world use of NanaBis, will provide further evidence for safety and tolerability and review the impact NanaBis has on current prescriptive medicines used in pain settings, thus bolstering Medlab’s goal of drug registration.

UK distribution agreement

Medlab has also recently executed a distribution agreement with nutritional supplement manufacturer Cultech Ltd that will see the company expand its nutraceutical business into the UK.

This exclusive distribution agreement follows the recent execution of a definitive agreement to expand Medlab’s nutraceutical business in the USA.

Similar to the previous US deal, the UK agreement provides minimal operating expenditure exposure for Medlab and provides for 20% royalties ex-factory under the transfer agreement.

This agreement focuses on two Medlab products:

  • ORSBiotic™: Part of the existing Medlab Australian and US nutraceutical ranges, a patented probiotic rehydration formulation; and
  • NanoCBD™: A new cannabinoid product utilising Magnesium and CBD from the newly manufactured NanoCBD™ product - the product utilises Medlab’s patented delivery platform, NanoCelle™.

Quick facts: Medlab Clinical Ltd

Price: 0.345 AUD

ASX:MDC
Market: ASX
Market Cap: $80.46 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Medlab Clinical Ltd named herein, including the promotion by the Company of Medlab Clinical Ltd in any Content on the Site, the Company...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Medlab Clinical forges ahead in new vitamin trials for chronic illnesses

Medlab Clinical Ltd (ASX:MDC) chief executive officer Sean Hall tells Proactive Investors how the company is tapping into new areas of its “therapeutic toolkit” to better assist those with chronic health conditions.   Hall says there has been a shortfall in the standard of...

on 8/5/19

3 min read